Skip to content

Merck & Co. MRK Treasury stock, shares (in shares)

Treasury stock, shares (in shares) at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
Zoetis logo
ZoetisZTS

Other financials

Income statement

See full
Revenue$16.3B+4.9%
Gross profit$12.1B-0.2%
Net income-$4.2B-183%
EPS (diluted)-$1.72-186%

Balance sheet

See full
Cash & equivalents$5.4B-38.2%
Total debt$49.1B+35.8%
Total equity$45.9B-5.1%
Total assets$128.69B+11.8%

Cash flow

See full
Operating cash flow$3.9B+56.7%
CapEx$991.0M-25.4%
Free cash flow$2.9B+150%

Valuation

See full
Market cap$317.37B+61.7%
Enterprise value$361.07B+60.4%
P/E35.5×+23.6×
P/S4.8×+1.7×

Profitability

See full
Gross margin73.9%-2.5pp
Net margin13.6%-13.7pp
FCF margin21.5%-5.2pp

Returns & leverage

See full
Return on equity19%-20.3pp
Debt / equity1.1×+0.3×
Current ratio1.3×-0.1×

Where this comes from

Reported directly by Merck & Co. in its filing.

Tagged under the XBRL concept us-gaap:TreasuryStockCommonShares.

The official record: Merck & Co.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Merck & Co.'s treasury stock, shares (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Merck & Co.'s treasury stock, shares (in shares)?
Merck & Co. (MRK) reported treasury stock, shares (in shares) of 1.1B in Q1 2026.
How has Merck & Co.'s treasury stock, shares (in shares) changed year-over-year?
Merck & Co.'s treasury stock, shares (in shares) increased by 4.4% year-over-year, from 1.1B to 1.1B.
What is the long-term trend for Merck & Co.'s treasury stock, shares (in shares)?
Over 4 years (2021 to 2025), Merck & Co.'s treasury stock, shares (in shares) has grown at a 1.2% compound annual growth rate (CAGR), from 1B to 1.1B.